MYRIAD GENETICS INC (MYGN) has 201 open-market insider trades by 38 insiders since 2006. Over the last six months insiders net bought $28K. The most active filer is Peter D. Meldrum, President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Jerry S. Lanchbury | CSO | — | 17 | $28.5M | 2021-10-09 |
| Mark Christopher Capone | Pres | — | 11 | $28.2M | 2019-09-30 |
| Richard M. Marsh | CLOVP | — | 12 | $15.0M | 2018-09-30 |
| Peter D. Meldrum | Pres | — | 20 | $13.3M | 2015-05-06 |
| Walter Gilbert Ph.D. | Dir | — | 13 | $12.0M | 2019-12-13 |
| Dennis Langer | Dir | — | 10 | $11.1M | 2022-06-02 |
| Jayne B. Hart | CPO | — | 4 | $9.8M | 2022-10-09 |
| Gary A. King | VP | — | 8 | $9.5M | 2019-09-30 |
| Adrian N. Hobden | Pres. Myriad Pharmaceuticals | — | 7 | $7.5M | 2009-06-08 |
| Paul J. Diaz | CEOPres | — | 1 | $7.2M | 2025-03-24 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Rashmi Kumar | Director | Sell | $67K | 2026-06-08 |
| Paul Bisaro | Director | Buy | $28K | 2026-05-14 |
| Samraat S. Raha | President | Buy | $200K | 2026-03-09 |
| S. Louise Phanstiel | Director | Buy | $495K | 2026-02-25 |
| Paul J. Diaz | CEO & President | Sell | $344K | 2024-10-11 |
| Dale Muzzey | CSO | Sell | $55K | 2024-09-11 |
Companies that share insiders with MYGN, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Paul J. Diaz | CEO & President | Sell | $401K | 2024-09-11 |
| Heinrich Dreismann | Director | Sell | $271K | 2024-09-09 |
| Colleen F. Reitan | Director | Sell | $2.6M | 2024-09-03 |
| Margaret Ancona | VP | Sell | $642K | 2024-08-21 |
| Rashmi Kumar | Director | Sell | $210K | 2024-08-19 |
| Daniel K. Spiegelman | Director | Sell | $334K | 2024-06-03 |
| Lee Nisley Newcomer | Director | Sell | $157K | 2024-05-13 |
| Paul J. Diaz | CEO & President | Sell | $7.2M | 2024-05-13 |
| Richard Bryan Riggsbee | CFO | Sell | $573K | 2023-12-01 |